Litcius/Paper detail

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie, Laura Moran, Richard Hafner, Florian von Groote-Bidlingmaier, Javier R. Lama, Justin Shenje, Jorge De Los Ríos, Kyla Comins, Joel Morganroth, Andreas H. Diacon, Yoninah Cramer, Kathleen Donahue, Gary Maartens, Oladapo Alli, Joan Gottesman, Maria Guevara, Chris Hikuam, Laura Hovind, Mats O. Karlsson, Jennifer McClaren, Helen McIlleron, William Murtaugh, Barbara A. Rolls, Akbar Shahkolahi, Lynnett Stone, Gerald Tegha, Jacob Tenai, Caryn M. Upton, Chanelle Wimbish

2021The Lancet Infectious Diseases124 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBedaquilineMoxifloxacinTuberculosisInternal medicineClinical endpointPopulationSputum cultureLevofloxacinRifampicinCulture conversionSputumRandomized controlled trialMycobacterium tuberculosisAntibioticsEnvironmental healthPathologyBiologyMicrobiologyTuberculosis Research and EpidemiologyCardiac electrophysiology and arrhythmiasPneumonia and Respiratory Infections